The Food and Drug Administration announced Saturday evening it has granted emergency use authorization for Regeneron Pharmaceuticals' antibody cocktail given to President Trump to treat his COVID-19 infection last month.

Details: Regeneron's two monoclonal antibodies, casirivimab and imdevimab, are for people who tested positive for the coronavirus and "who are at high risk for progressing to severe COVID-19," the FDA noted in a statement.

• Regeneron said in a statement it expects to have doses of the treatment, called REGEN-COV2, ready for some 80,000 patients by the end of November, about 200,000 patients by the first week of January, and approximately 300,000 patients in total by the end of January 2021.

Go deeper: Regeneron CEO: Trump's success with antibody cocktail is not evidence of cure

Editor's note: This a breaking news story. Please check back for updates